I maintain my neutral position on the GMO U.S. Quality ETF (QLTY), an actively managed exchange-traded fund that I have previously evaluated twice this year. Despite some positive developments, a compelling bullish argument has not yet emerged for this fund.

Since the beginning of the year, QLTY has shown a slight underperformance relative to IVV, and I anticipate this trend of lagging the broader market to continue until 2027. Although the growth and GARP (Growth at a Reasonable Price) attributes of QLTY's concentrated, technology-heavy portfolio have improved since May, its price-to-earnings growth (PEG) ratio remains notably higher than IVV's, justifying a cautious stance.

Nevertheless, QLTY boasts exceptionally strong quality metrics, achieved through a stringent screening process. This makes it an attractive option for investors who prioritize high-quality assets in their portfolios.

Investors should always prioritize thorough due diligence and consider multiple factors when making investment decisions. While market trends and ratios provide valuable insights, a holistic view that includes risk tolerance, investment horizons, and personal financial goals is essential. Continuous learning and adaptability to changing market conditions are key to successful long-term investing.